[A23-56] Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V
Last updated 15.09.2023
Commission awarded on 14.06.2023 by the Federal Joint Committee (G-BA).
Heart and circulation
Children and adolescents aged 1 year or older with symptomatic chronic heart failure with left ventricular systolic dysfunction
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.